MedPath

A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic Dermatitis

Not Applicable
Not yet recruiting
Conditions
Atopic Dermatitis (AD)
Interventions
Drug: Vehicle
Registration Number
NCT07184645
Lead Sponsor
Otsuka Pharmaceutical Co., Ltd.
Brief Summary

To investigate the superiority of 0.3% OPA-15406 foam to the vehicle in children with atopic dermatitis (AD)

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
198
Inclusion Criteria
  • Participants who have been diagnosed with AD based on the Diagnostic Criteria for Atopic Dermatitis (Criteria of the Japanese Dermatological Association)
  • Participants who have an affected area covering from 5% to 40% of their body surface area (excluding the scalp) at the screening and baseline examinations
  • Participants with an IGA score of 2 or 3 at the screening and baseline examinations
Exclusion Criteria
  • Participants who experienced an acute exacerbation of AD or contact dermatitis within 28 days prior to the baseline examination
  • Participants who have been treated with OPA-15406 ointment in the past

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
OPA-15406 foamOPA-15406-
VehicleVehicle-
Primary Outcome Measures
NameTimeMethod
Success rate in Investigator's Global Assessment (IGA)Week 4

The investigator or subinvestigator assessed the skin symptoms using IGA. The investigator or subinvestigator scored the severity (0 = clear, 1 = almost clear, 2 =mild, 3 = moderate, 4 = severe/very severe) of the overall symptoms of the treatment area (erythema, infiltration, papules, effusion and scab formation) from baseline to Week 4. Incidence of success in IGA is defined as the rate of participants whose IGA score is 0 (clear) or 1 (almost clear) and has improved by at least 2 grades (responders) from baseline.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Sumire Dermatology Clinic

🇯🇵

Tokyo, Japan

Sumire Dermatology Clinic
🇯🇵Tokyo, Japan

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.